[go: up one dir, main page]

MX2010003442A - Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo. - Google Patents

Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo.

Info

Publication number
MX2010003442A
MX2010003442A MX2010003442A MX2010003442A MX2010003442A MX 2010003442 A MX2010003442 A MX 2010003442A MX 2010003442 A MX2010003442 A MX 2010003442A MX 2010003442 A MX2010003442 A MX 2010003442A MX 2010003442 A MX2010003442 A MX 2010003442A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
glycogen phosphorylase
phosphorylase inhibitor
inhibitor compound
compound
Prior art date
Application number
MX2010003442A
Other languages
English (en)
Inventor
Francis X Tavares
Stephen Andrew Thomson
Scott Howard Dickerson
Steven Meagher Sparks
Pierette Banker
Dulce Maria Garrido
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2010003442A publication Critical patent/MX2010003442A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Esta invenci?n se refiere a un compuesto novedoso, el cual es un inhibidor de fosforilasa de glic?geno, y a su uso en el tratamiento de diabetes y otras condiciones asociadas con la misma. La invenci?n se refiere adem?s a una composici?n farmac?utica que contiene el compuesto, y a procesos para la preparaci?n del compuesto y de la composici?n farmac?utica.
MX2010003442A 2007-09-28 2008-09-25 Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo. MX2010003442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97586507P 2007-09-28 2007-09-28
PCT/US2008/077626 WO2009045831A1 (en) 2007-09-28 2008-09-25 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof

Publications (1)

Publication Number Publication Date
MX2010003442A true MX2010003442A (es) 2010-04-21

Family

ID=40120238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003442A MX2010003442A (es) 2007-09-28 2008-09-25 Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo.

Country Status (16)

Country Link
US (1) US20100234433A1 (es)
EP (1) EP2197845A1 (es)
JP (1) JP2010540553A (es)
KR (1) KR20100075568A (es)
CN (1) CN101861303A (es)
AU (1) AU2008309004A1 (es)
BR (1) BRPI0817445A2 (es)
CA (1) CA2701020A1 (es)
CO (1) CO6321157A2 (es)
CR (1) CR11397A (es)
DO (1) DOP2010000088A (es)
EA (1) EA201000392A1 (es)
MA (1) MA31775B1 (es)
MX (1) MX2010003442A (es)
WO (1) WO2009045831A1 (es)
ZA (1) ZA201002182B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK66798A3 (en) * 1995-11-24 1999-01-11 Smithkline Beecham Spa Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use
MX2007005590A (es) * 2004-11-09 2007-05-24 Smithkline Beecham Corp Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.

Also Published As

Publication number Publication date
CO6321157A2 (es) 2011-09-20
CN101861303A (zh) 2010-10-13
BRPI0817445A2 (pt) 2015-10-27
MA31775B1 (fr) 2010-10-01
DOP2010000088A (es) 2010-07-15
JP2010540553A (ja) 2010-12-24
ZA201002182B (en) 2011-05-25
CA2701020A1 (en) 2009-04-09
KR20100075568A (ko) 2010-07-02
AU2008309004A1 (en) 2009-04-09
EP2197845A1 (en) 2010-06-23
EA201000392A1 (ru) 2010-10-29
WO2009045831A1 (en) 2009-04-09
US20100234433A1 (en) 2010-09-16
CR11397A (es) 2010-05-24

Similar Documents

Publication Publication Date Title
MX2010003440A (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
JO2701B1 (en) Vehicles
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
IN2012DN00721A (es)
IN2012DN01233A (es)
UA98651C2 (ru) Спироциклы как ингибиторы 11-бета гидроксилстероиддегидрогеназы типа 1
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MY155695A (en) Quinoxalinedione derivatives
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
TN2009000129A1 (en) Indole compound
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
GB0625648D0 (en) Compounds
PL2021337T3 (pl) Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MY148079A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2010003442A (es) Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo.
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MY152475A (en) Fused ring compounds and use thereof
MX2010009536A (es) Amidas de acido 5-oxo-2,3,4,5-tetrahidro-benzo[b]oxepin-4-carboxil ico y amidas de acido 2,3-dihidro-benzo[b]oxepin-4-carboxilico para el tratamiento y la prevension de la diabetes tipo 1 y 2.
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
SG158091A1 (en) Imidazoazepinone compounds
GEP20135832B (en) Benzothiazines derivatives, preparation thereof, and their application as drugs
TW200745122A (en) New compounds I

Legal Events

Date Code Title Description
FA Abandonment or withdrawal